How health technology reassessment can support disinvestment in China's national drug reimbursement list.
Where this comes from
- Record sourced from PubMed, PMID 37321624.
- Also identified by DOI 10.1136/bmj-2021-068917 and PMC identifier 10266436.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A requirement to assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment, say <b>Lizheng Shi</b> <b>and colleagues</b>
Medical subject headings
- Biomedical Technology